NCT05706064

Brief Summary

Using online questionnaires, we will obtain data regarding COVID-19 infection and treatment, including incidence rate, hospitalization rate, severity of the infection, medications, mortality rate, etc, in both hospital and communities after the change of disease control policy in China.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 28, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 29, 2023

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 31, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

January 24, 2024

Status Verified

January 1, 2024

Enrollment Period

4 months

First QC Date

January 29, 2023

Last Update Submit

January 22, 2024

Conditions

COVID-19Infections

Outcome Measures

Primary Outcomes (1)

  • All-cause mortality

    Quickly obtain the all-cause mortality in patients with COVID-19

    6 months

Secondary Outcomes (4)

  • Incidence rate of COVID-19 infection

    6 months

  • Medication for COVID-19 treatment

    6 months

  • Hospitalization rate due to COVID-19 infection

    6 months

  • Severity of COVID-19 infection

    6 months

Study Arms (1)

COVID-19 Infection

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All population from hospital and community

You may qualify if:

  • N/A

You may not qualify if:

  • N/A

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ling Tao

Xi'an, Shannxi, 710032, China

Location

MeSH Terms

Conditions

COVID-19Infections

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Ling Tao, MD, Ph.D.

    Xijing Hospital

    STUDY CHAIR

  • Chao Gao, MD, Ph.D.

    Xijing Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor in Cardiology, Director of the department of Cardiology

Study Record Dates

First Submitted

January 29, 2023

First Posted

January 31, 2023

Study Start

December 28, 2022

Primary Completion

April 30, 2023

Study Completion

June 30, 2023

Last Updated

January 24, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)